Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2005 3
2006 1
2007 3
2008 3
2009 4
2010 4
2011 1
2012 3
2013 4
2014 8
2015 5
2016 10
2017 8
2018 8
2019 10
2020 3
2021 8
2022 10
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Pre-treatment with β-hydroxybutyrate mitigates cisplatin-induced acute kidney injury.
Kim MJ, Kim YS, Kim SR, Lee DW, Lee SB, Kim IY. Kim MJ, et al. Biochem Biophys Res Commun. 2024 Feb 5;695:149482. doi: 10.1016/j.bbrc.2024.149482. Epub 2024 Jan 5. Biochem Biophys Res Commun. 2024. PMID: 38211529
beta-Hydroxybutyrate (beta-HB), the primary circulating ketone body, plays a dual role as both a metabolic fuel and an endogenous signaling molecule, offering diverse systemic benefits. Recent studies have highlighted the renoprotective effects of exogenous beta-HB therapy …
beta-Hydroxybutyrate (beta-HB), the primary circulating ketone body, plays a dual role as both a metabolic fuel and an endogenous signaling …
The Impact of 131I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma.
Park HJ, Choi JY, Kim BK, Hong KT, Kim HY, Kim IH, Cheon GJ, Cheon JE, Park SH, Kang HJ. Park HJ, et al. Children (Basel). 2023 Dec 18;10(12):1936. doi: 10.3390/children10121936. Children (Basel). 2023. PMID: 38136138 Free PMC article.
Comparing the (131)I-MIBG combined group and other groups, the five-year OS rates were 82.1% and 79.7% (p = 0.655), and the five-year EFS rates were 69.2% and 69.6% (p = 0.922), respectively. Among the adverse effects of grade 3 or 4, the incidence of liver enzyme e …
Comparing the (131)I-MIBG combined group and other groups, the five-year OS rates were 82.1% and 79.7% (p = 0.655), and the five-year EFS ra …
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Park S, et al. J Clin Oncol. 2024 Apr 10;42(11):1241-1251. doi: 10.1200/JCO.23.01891. Epub 2023 Oct 20. J Clin Oncol. 2024. PMID: 37861993 Clinical Trial.
The safety profile of the ABCP arm was comparable with that previously reported, with no additional safety signals, but higher rates of treatment-related adverse events were observed compared with the PC arm. CONCLUSION: To our knowledge, this study is the first randomized …
The safety profile of the ABCP arm was comparable with that previously reported, with no additional safety signals, but higher rates of trea …
Feasibility of low-dose radiotherapy for patients with stage I/II extranodal NK-/T-cell lymphoma, nasal type achieving complete response after l-asparaginase-containing chemotherapy.
Kim JS, Choi N, Kim IH, Kim TM, Jeon YK, Chang JH. Kim JS, et al. Clin Transl Radiat Oncol. 2022 Nov 3;38:155-160. doi: 10.1016/j.ctro.2022.10.014. eCollection 2023 Jan. Clin Transl Radiat Oncol. 2022. PMID: 36466747 Free PMC article.

Survival outcomes were not affected either by the administration of l-ASP or EQD2 < 40 Gy in patients displaying CR after l-ASP. Adverse events (AEs) Grade 2 were significantly reduced with EQD2 < 40 Gy, compared with EQD2 40 Gy. ...Decreasing RT doses in patients wi

…

Survival outcomes were not affected either by the administration of l-ASP or EQD2 < 40 Gy in patients displaying CR after l-ASP. Adver

…
97 results